MedPath

Leveraging the Emergency Department to Engage African American Women in HIV Pre-Exposure Prophylaxis

Not Applicable
Completed
Conditions
HIV Infections
Interventions
Behavioral: iPrEP
Behavioral: Usual Care
Registration Number
NCT03930654
Lead Sponsor
The University of Texas Health Science Center, Houston
Brief Summary

African American (AA) women are more vulnerable to HIV infection than other women. Truvada, when used as pre-exposure prophylaxis (PrEP), is one of the most effective approaches for HIV prevention; however, PrEP use among AA women remains low and has not responded to traditional interventions. This study proposes for the first time an innovative computer-based motivational intervention, increasing PrEP uptake (iPrEP), which couples motivational messages woven into a traditional survey to raise awareness of risky sex and substance use behaviors.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • Current HIV negative status (based on ED' HIV test outcome)
  • Condomless sex in the last 3 months
  • Substance use in the last 3 months
  • HIV testing during ED visit (usual care)
  • Has a non-emergent health condition
  • Has a working mobile device with them
Exclusion Criteria
  • Ineligible for PrEP (see eligibility criteria to the right)
  • Assigned male at birth
  • An HIV positive status
  • Currently taking medication that are known contraindications for PrEP (brand name: Truvada)
  • Currently on PrEP

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
iPrEP InterventioniPrEPiPrEP Intervention: * Women will receive the iPrEP intervention on an iPAD Air tablet device * iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument * iPrEP uses qualitative themes * iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence * Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument * Scales were modified (in some cases) for cultural competency and tailoring to women
iPrEP InterventionUsual CareiPrEP Intervention: * Women will receive the iPrEP intervention on an iPAD Air tablet device * iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument * iPrEP uses qualitative themes * iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence * Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument * Scales were modified (in some cases) for cultural competency and tailoring to women
Usual CareUsual CareControl Intervention: * Women will receive usual care * Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use * Social worker will offer a list of substance abuse treatment referral agencies
Primary Outcome Measures
NameTimeMethod
Number of participants with an increased willingness for pre-exposure prophylaxis (PrEP) uptake6 months

Participants will be assessed for social norms and risk.

Secondary Outcome Measures
NameTimeMethod
iPrEP feasibility and acceptability as assessed by the number of participants who believe that they had more information to make a better decision about being in a PrEP program after completing the survey interventionbaseline

As part of the survey, participants will be asked if they believe that they had more information to make a better decision about being in a PrEP program after completing the survey intervention.

iPrEP feasibility and acceptability as assessed by how much participant liked or disliked completing the surveybaseline

As part of the survey, participants will asked "How much did you like or dislike completing this questionnaire?" and will choose one of the following 5 categorical choices: Liked it, Liked it somewhat, Neither liked nor disliked it, Disliked it somewhat, Disliked it

Number of participants with decrease in substance use6 months
Number of participants with HIV seroconversion6 months
Number of participants with a new sexually transmitted disease diagnosis6 months
iPrEP feasibility and acceptability as assessed by how often participants relied on the survey questions being read aloud to be able to answer thembaseline

As part of the survey, participants will asked "As you completed this questionnaire, how often did you rely on the questions being read aloud to be able to answer them?" and will choose one of the following 4 categorical choices: For all the questions, For most of the questions, For some of the questions, For none of the questions

iPrEP feasibility and acceptability as assessed by the kind of help that participants needed from site staff in order to complete the surveybaseline

As part of the survey, participants will asked "What kind of help did you need? Please check all that apply" and will choose among the following categorical 4 choices: I had to have some of the questions explained to me, I needed help using the iPAD, I needed to have the questionnaire read to me by a staff member, I needed help for a different reason

Number of participants with decreased high risk sex6 months
iPrEP feasibility and acceptability as assessed by how participants felt about the length of the surveybaseline

As part of the survey, participants will asked how they felt about the length of the survey and will choose one of the following 3 categorical choices: Too long, Too short, The right length

iPrEP feasibility and acceptability as assessed by number of participants who needed help from site staff in order to complete the surveybaseline

As part of the survey, participants will be asked if they needed help from site staff in order to complete the survey.

Trial Locations

Locations (1)

The University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath